p16-L16R-FLAG protein levels were increased up to p16-WT-FLAG levels upon treatment with another proteasome inhibitor, bortezomib, when expressed in Panc1 cells and RPM1-7951 melanoma cells, a cell line homozygous for p16-L16R (Fig. S3, C and D). Here, CDKN2A is linked to melanoma.